Background: It has been demonstrated that cognitive behavioural therapy (CBT) has a moderate effect on symptom reduction and on general well being of patients suffering from psychosis. However, questions regarding the specific efficacy of CBT, the treatment safety, the cost-effectiveness, and the moderators and mediators of treatment effects are still a major issue. The major objective of this trial is to investigate whether CBT is specifically efficacious in reducing positive symptoms when compared with non-specific supportive therapy (ST) which does not implement CBT-techniques but provides comparable therapeutic attention. Methods: The POSITIVE study is a multicenter, prospective, single-blind, parallel group, randomised clinical trial, ...
Background: Clozapine (clozaril, Mylan Products Ltd) is a first-choice treatment for people withschi...
BACKGROUND: A series of small, mainly uncontrolled, studies have suggested that techniques adapted f...
© Queen’s Printer and Controller of HMSO 2019. Background: Clozapine (clozaril, Mylan Products Ltd) ...
Background: It has been demonstrated that cognitive behavioural therapy (CBT) has a moderate effect ...
Background: It has been demonstrated that cognitive behavioural therapy (CBT) has a moderate effect ...
Since the early 1990s, cognitive behavioral therapy (CBT) has been increasingly used as an adjunctiv...
Despite a historical pessimism about the possibility of helping people with schizophrenia using psyc...
BackgroundEvidence on cost-effectiveness is important to make well-informed decisions regarding care...
Background: There is increasing evidence that cognitive-behavioural therapy can be an effective inte...
Meta-analyses show that cognitive behaviour therapy for psychosis (CBT-P) improves distressing posit...
Background: At least 40% of people with psychosis have persistent distressing symptoms despite optim...
BACKGROUND: Recent reviews of randomized controlled trials have concluded that cognitive behaviour t...
BACKGROUND: Intervention trials for young people at ultra high risk (UHR) for psychosis have shown c...
Purpose: to answer the clinical PICOT question: For patients with schizophrenia how does CBT (cognit...
Acknowledgments We thank all the participants who agreed to take part in the trial. This study was s...
Background: Clozapine (clozaril, Mylan Products Ltd) is a first-choice treatment for people withschi...
BACKGROUND: A series of small, mainly uncontrolled, studies have suggested that techniques adapted f...
© Queen’s Printer and Controller of HMSO 2019. Background: Clozapine (clozaril, Mylan Products Ltd) ...
Background: It has been demonstrated that cognitive behavioural therapy (CBT) has a moderate effect ...
Background: It has been demonstrated that cognitive behavioural therapy (CBT) has a moderate effect ...
Since the early 1990s, cognitive behavioral therapy (CBT) has been increasingly used as an adjunctiv...
Despite a historical pessimism about the possibility of helping people with schizophrenia using psyc...
BackgroundEvidence on cost-effectiveness is important to make well-informed decisions regarding care...
Background: There is increasing evidence that cognitive-behavioural therapy can be an effective inte...
Meta-analyses show that cognitive behaviour therapy for psychosis (CBT-P) improves distressing posit...
Background: At least 40% of people with psychosis have persistent distressing symptoms despite optim...
BACKGROUND: Recent reviews of randomized controlled trials have concluded that cognitive behaviour t...
BACKGROUND: Intervention trials for young people at ultra high risk (UHR) for psychosis have shown c...
Purpose: to answer the clinical PICOT question: For patients with schizophrenia how does CBT (cognit...
Acknowledgments We thank all the participants who agreed to take part in the trial. This study was s...
Background: Clozapine (clozaril, Mylan Products Ltd) is a first-choice treatment for people withschi...
BACKGROUND: A series of small, mainly uncontrolled, studies have suggested that techniques adapted f...
© Queen’s Printer and Controller of HMSO 2019. Background: Clozapine (clozaril, Mylan Products Ltd) ...